Anti-PD-1 monoclonal antibody combined with chemotherapy for porocarcinoma: a case report and literature review - Top-Institutions - MDSpire

Anti-PD-1 monoclonal antibody combined with chemotherapy for porocarcinoma: a case report and literature review

  • By

  • Guofa Zhao

  • Guiliang Han

  • Xiaomei Yang

  • Youchao Jia

  • May 11, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    University of Milan
    University of Milan

    Milan, Lombardy

    Key Differentiators

    • Oncology

  • #3

    European Institute of Oncology
    European Institute of Oncology

    Milan, Lombardy

    Key Differentiators

    • Oncology

  • #4

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

  • #5

    Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
    Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology

Original Source(s)

Anti-PD-1 monoclonal antibody combined with chemotherapy for porocarcinoma: a case report and literature review

  • by Guofa Zhao, Guiliang Han, Xiaomei Yang, Youchao Jia

  • May 11, 2026

Related Content

Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma

Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship

Recurrent IDH-mutant astrocytoma WHO grade 4 diagnosed during pregnancy: case report with literature review